ezetimibe has been researched along with Fatty Liver, Nonalcoholic in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 26 (78.79) | 24.3611 |
| 2020's | 7 (21.21) | 2.80 |
| Authors | Studies |
|---|---|
| Canet, MJ; Cherrington, NJ; Fisher, CD; Hardwick, RN; Street, SM | 1 |
| Farrell, GC; Horn, CL; Ioannou, GN; Morales, AL; Savard, C | 1 |
| Bae, JH; Chang, Y; Jang, JY; Jeong, SW; Kim, HS; Kim, SG; Kim, YS; Lee, SH; Lee, WM; Moon, JE; Yoo, JJ | 1 |
| Averna, M; Cabibbi, D; Caldarella, R; Cefalù, AB; Ciaccio, M; Craxi, A; Giammanco, A; Muratore, R; Noto, D; Petta, S; Porcasi, R; Spina, R | 1 |
| Cha, BS; Cho, Y; Choi, JY; Kang, ES; Kim, YE; Lee, BW; Lee, M; Lee, YH; Rhee, H | 1 |
| Chung, KS; Gee, HY; Kim, DY; Park, JY | 1 |
| Athyros, VG; Doumas, M; Imprialos, K; Stavropoulos, K | 1 |
| Fras, Z; Mikhailidis, DP | 1 |
| Di Mauro, S; Di Pino, A; Ferrara, V; Filippello, A; Marchisello, S; Piro, S; Purrello, F; Rabuazzo, AM; Scamporrino, A; Scicali, R; Urbano, F | 1 |
| Ahn, H; Cheung, RC; Jun, DW; Kim, HJ; Lee, HY; Nguyen, MH; Oh, H; Saeed, WK | 1 |
| Blazing, M; Cannon, CP; Chung, RT; Corey, KE; Giugliano, RP; O'Donoghue, ML; Park, JG; Simon, TG | 1 |
| Pitha, J | 1 |
| Cheon, GJ; Jun, BG | 1 |
| Farrell, GC; Gan, LT; Haigh, WG; Ioannou, G; Larter, CZ; Teoh, NC; Van Rooyen, DM; Yeh, MM | 1 |
| Arai, K; Honda, M; Kaneko, S; Kato, K; Kita, Y; Misu, H; Mizukoshi, E; Nakamura, M; Ota, T; Sunagozaka, H; Takamura, T; Takeshita, Y; Yamada, K; Yamashita, T; Zen, Y | 1 |
| Musso, G | 1 |
| Guo, Y; Liang, Y; Liu, S; Ren, Q; Wang, X; Wu, T | 1 |
| Ang, B; Bettencourt, R; Bhatt, A; Brenner, DA; Ehman, R; Haufe, W; Hernandez, L; Hooker, C; Hooker, J; Jain, R; Kono, Y; Lin, GY; Loomba, R; Nguyen, P; Noureddin, M; Richards, L; Salotti, J; Sirlin, CB; Soaft, L; Valasek, MA; Yin, M | 1 |
| Farrell, GC; Haigh, WG; Ioannou, GN; Savard, C; Teoh, NC; Van Rooyen, DM; Yeh, MM | 1 |
| Eguchi, Y; Fujita, K; Honda, Y; Hyogo, H; Imajo, K; Kessoku, T; Kirikoshi, H; Mawatari, H; Nakajima, A; Nozaki, Y; Ogawa, Y; Ono, M; Saito, S; Sumida, Y; Taguri, M; Tomeno, W; Wada, K; Yoneda, M | 1 |
| Averna, M | 1 |
| Drozd, VIu; Haĭdychuk, VS; Khukhlina, OS; Kosar, LIu; Mandryk, OIe | 1 |
| Bae, SH; Cha, BS; Chun, Y; Han, DH; Jeong, H; Ji, HW; Kim, G; Kim, J; Kim, SH; Komatsu, M; Lee, DH; Lee, HY; Lee, JS; Lee, M; Lee, MJ; Lee, YH; Lee, YS; Min, BS; Nam, KT; Park, JS; Sung, SH | 1 |
| Chung, RT; Corey, KE; Giugliano, R; Simon, TG | 1 |
| Ahn, SC; Jang, HJ; Jeon, TI; Kim, KY; Osborne, TF; Park, KI; Seo, J; Seo, YK; Shin, IW; Suh, PG; Yang, YR | 1 |
| Bettencourt, R; Hamilton, G; Heba, E; Lin, GY; Lin, SC; Loomba, R; Lunde, O; Sirlin, CB; Valasek, MA | 1 |
| Gao, X; Jacobs, RL; Kassiri, Z; Lingrell, S; Takawale, A; van der Veen, JN; Vance, DE | 1 |
| Fukui, M; Hasegawa, G; Itoh, Y; Minami, M; Mitsuyoshi, H; Nakamura, N; Obayashi, H; Ohta, M; Okanoue, T; Park, H; Shima, T; Yamaguchi, K; Yasui, K; Yoshikawa, T | 1 |
| Yoshida, M | 1 |
| Fujita, K; Imajo, K; Kirikoshi, H; Mawatari, H; Nakajima, A; Saito, S; Yoneda, M | 1 |
| Gotoh, T; Hashimoto, M; Kawanami, Y; Moritani, A; Shiwa, T; Yokoyama, T | 1 |
| Cassader, M; Gambino, R; Musso, G | 1 |
| Fujisawa, K; Kuwashiro, S; Matsumoto, T; Nishina, H; Oishi, T; Sakaida, I; Terai, S | 1 |
7 review(s) available for ezetimibe and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Role of Cholesterol-Associated Steatohepatitis in the Development of NASH.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cholesterol, Dietary; Ezetimibe; Fatty Liver; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Risk Factors | 2022 |
What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Topics: Anticholesteremic Agents; Diffusion of Innovation; Drug Therapy, Combination; Ezetimibe; Forecasting; Gastroenterology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liver; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Factors; Risk Reduction Behavior; Treatment Outcome | 2019 |
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis.
Topics: Anticholesteremic Agents; Ezetimibe; Humans; Non-alcoholic Fatty Liver Disease; Severity of Illness Index | 2019 |
The effect of ezetimibe on NAFLD.
Topics: Animals; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Lipid Metabolism; Liver; Non-alcoholic Fatty Liver Disease; Treatment Outcome | 2015 |
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Risk Reduction Behavior; Thrombophilia | 2016 |
Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Fatty Liver; Humans; Liver; Membrane Proteins; Membrane Transport Proteins; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease | 2011 |
Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update.
Topics: Animals; Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic | 2011 |
10 trial(s) available for ezetimibe and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial.
Topics: Adult; Alanine Transaminase; Ezetimibe; Female; Health Education; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Nutrition Therapy; Nutritional Sciences; Prospective Studies; Republic of Korea | 2021 |
Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial.
Topics: Biopsy; Double-Blind Method; Ezetimibe; Humans; Life Style; Non-alcoholic Fatty Liver Disease; Treatment Outcome | 2022 |
Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study).
Topics: Diabetes Mellitus, Type 2; Elasticity Imaging Techniques; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease | 2022 |
Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease).
Topics: Aged; Anticholesteremic Agents; Chronic Disease; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Male; Non-alcoholic Fatty Liver Disease; Simvastatin; Treatment Outcome | 2021 |
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Female; Humans; Internationality; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Risk Factors; Secondary Prevention; Severity of Illness Index | 2018 |
The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.
Topics: Aged; Anticholesteremic Agents; Area Under Curve; Azetidines; Biopsy; Carnitine; Cholesterol; Ezetimibe; Fatty Acids; Female; Fibrosis; Gene Expression Profiling; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Insulin; Liver; Male; Middle Aged; Myofibroblasts; Non-alcoholic Fatty Liver Disease; Oligonucleotide Array Sequence Analysis; Signal Transduction; Transaminases; Treatment Outcome | 2014 |
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
Topics: Anticholesteremic Agents; Azetidines; Double-Blind Method; Elasticity Imaging Techniques; Ezetimibe; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease | 2015 |
LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Cross-Sectional Studies; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Risk Factors | 2014 |
Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Cross-Sectional Studies; Diet, Fat-Restricted; Double-Blind Method; Ezetimibe; Female; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome | 2017 |
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.
Topics: Adult; Anticholesteremic Agents; Azetidines; Biomarkers; Biopsy; Drug Administration Schedule; Ezetimibe; Fatty Liver; Female; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome | 2011 |
16 other study(ies) available for ezetimibe and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
Topics: Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Biliary Tract; Biological Transport; Choline Deficiency; Diet; Ezetimibe; Fatty Liver; Glucuronosyltransferase; Intestinal Mucosa; Liver; Male; Membrane Transport Proteins; Methionine; Multidrug Resistance-Associated Proteins; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley | 2012 |
Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models.
Topics: Adult; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Ezetimibe; Glucose; Humans; Liver; Mice; Non-alcoholic Fatty Liver Disease | 2023 |
Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Inflammation Mediators; Italy; Lipids; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; PCSK9 Inhibitors; Prospective Studies; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Triglycerides | 2021 |
Improved management of patients after acute coronary syndrome: using nonalcoholic fatty liver disease fibrosis score and ezetimibe?
Topics: Acute Coronary Syndrome; Azetidines; Ezetimibe; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2018 |
The utility of ezetimibe therapy in nonalcoholic fatty liver disease.
Topics: Ezetimibe; Humans; Liver; Non-alcoholic Fatty Liver Disease | 2019 |
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Topics: Adiponectin; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Heptanoic Acids; Insulin; Liver; MAP Kinase Signaling System; Metabolic Syndrome; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; Pyrroles | 2013 |
Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD?
Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Female; Glucose; Humans; Male; Non-alcoholic Fatty Liver Disease | 2014 |
Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.
Topics: Acetyl-CoA Carboxylase; Animals; Anticholesteremic Agents; Azetidines; CD36 Antigens; Diet, High-Fat; Ezetimibe; Fatty Acids; Fibrosis; Hyperinsulinism; Insulin Resistance; Lipid Metabolism; Lipogenesis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Stearoyl-CoA Desaturase | 2014 |
Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Heptanoic Acids; Inflammasomes; Kupffer Cells; Liver; Mice; Mice, Mutant Strains; Non-alcoholic Fatty Liver Disease; Pyrroles | 2015 |
[The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II].
Topics: Adenine; Anticholesteremic Agents; Azetidines; Carnitine; Drug Combinations; Endothelium, Vascular; Essential Hypertension; Ezetimibe; Fosinopril; Humans; Hypertension; Non-alcoholic Fatty Liver Disease; Obesity; Vascular Diseases | 2014 |
Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Apoptosis; Diet; Ezetimibe; Gene Expression Regulation; Glutathione Transferase; Humans; Kelch-Like ECH-Associated Protein 1; Liver; Male; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Sequestosome-1 Protein; Signal Transduction | 2016 |
SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy.
Topics: Animals; Anticholesteremic Agents; Autophagosomes; Autophagy; Cells, Cultured; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Group VI Phospholipases A2; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Signal Transduction; Sterol Regulatory Element Binding Protein 2; Triglycerides | 2016 |
Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
Topics: Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Ezetimibe; Fenofibrate; Humans; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Oxidation-Reduction; Phosphatidylethanolamine N-Methyltransferase; Triglycerides | 2017 |
Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis.
Topics: Anticholesteremic Agents; Azetidines; Carrier Proteins; Ezetimibe; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease | 2011 |
The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD).
Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Liver; Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Ultrasonography | 2011 |
Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model.
Topics: Animals; Anticholesteremic Agents; Azetidines; Disease Models, Animal; Ezetimibe; Fatty Acids; Fatty Liver; Inflammation; Liver; Non-alcoholic Fatty Liver Disease; Oryzias | 2012 |